This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
MIRACLE was a randomized phase 2 clinical trial in metastatic breast cancer. The registry describes a parallel, unmasked treatment design with 200 enrolled participants and two arms. The registered primary endpoint is progression-free survival, defined as the time from randomization to disease progression, relapse, or death.
| Feature | MIRACLE |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Condition | Metastatic Breast Cancer |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 200 |
| Number of arms | 2 |
| Lead sponsor | Chinese Academy of Medical Sciences |
| Start date | 2014-12 |
| Primary completion date | 2016-12 |
| ClinicalTrials.gov | NCT02313051 |
2. Clinical Question
The trial addresses a treatment question in metastatic breast cancer: how does a randomized treatment strategy involving everolimus, goserelin, and letrozole compare with the other randomized arm with respect to progression-free survival?
Population
Patients enrolled with metastatic breast cancer.
Interventions
Everolimus, goserelin, and letrozole are identified as the trial interventions.
Comparator
The registry identifies two randomized arms, but the available record does not provide the arm-specific intervention assignments needed to characterize each arm in greater detail.
Primary question
Does the randomized treatment comparison affect progression-free survival, defined from randomization to disease progression, relapse, or death?
3. Trial Design
The design is statistically straightforward at its highest level: randomization creates two groups for comparison, the groups are followed prospectively, and the primary endpoint is a time-to-event outcome. The important statistical feature is therefore not simply that participants were randomized, but that progression-free survival incorporates both the timing of an event and the possibility that some participants remain event-free at the end of available follow-up.
4. Endpoints
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Progression free survival | The time from randomization to the time of disease progression or relapse or death | 6 months after last patient was evaluated |
The endpoint is explicitly time-based. A participant contributes information according to how long they remain free of disease progression, relapse, or death. This differs from a simple binary endpoint such as whether progression occurred at a fixed calendar date, because participants can experience the event at different times and some may not experience the event during the observation period.
The registry specifies a composite time-to-event endpoint. An event occurs when disease progression, relapse, or death occurs; the registry gives the primary endpoint time frame as 6 months after the last patient was evaluated.
5. Planned Analysis
The registry identifies progression-free survival as the primary endpoint and specifies that it is measured from randomization until disease progression, relapse, or death. No primary endpoint results or posted statistical analyses are reported in the ClinicalTrials.gov record.
For an endpoint of this type, the standard statistical framework is survival analysis. The usual first step is to estimate the PFS distribution within each randomized arm using the Kaplan-Meier method. This produces a curve showing the estimated probability of remaining free from the defined event as follow-up progresses.
Here, di represents the number of events at event time ti, while ni represents the number of participants at risk immediately before that time.
A treatment-group comparison for PFS would commonly use a log-rank test, potentially stratified if the randomization design specified stratification factors. A Cox proportional-hazards model would commonly be used to estimate a hazard ratio and its confidence interval when that model is appropriate.
Those methods answer related but distinct questions. The Kaplan-Meier curve describes the estimated event-free experience over time. The log-rank test evaluates evidence of a difference between survival distributions. The Cox model summarizes the relative event hazard through a hazard ratio and can incorporate prespecified covariates or strata.
6. Statistical Methods Explained
Why is progression-free survival a time-to-event endpoint?
Progression-free survival records when progression, relapse, or death occurs rather than simply whether an event ever occurred. Two participants can both experience progression but contribute very different amounts of event-free follow-up. Time-to-event methods preserve that timing information.
Why would Kaplan-Meier estimation be appropriate?
Clinical follow-up is rarely identical for every participant. Some participants experience the endpoint during observation, while others may remain event-free when follow-up ends. Kaplan-Meier estimation handles these right-censored observations while estimating the probability of remaining event-free over time.
What would a PFS hazard ratio mean?
If a Cox model were used, the hazard ratio would compare the estimated instantaneous rates of progression, relapse, or death between the randomized groups. A hazard ratio below 1 would indicate a lower estimated event hazard for the numerator group relative to the denominator group. It would not mean that the same percentage of participants avoided progression, nor would it directly equal a difference in median PFS.
Why does censoring matter?
A participant who has not experienced progression, relapse, or death by the end of available observation is not necessarily equivalent to a participant who will never experience the event. Survival analysis therefore treats the participant as censored at the relevant follow-up point rather than assigning an artificial event time.
What does the 6-month time frame mean?
The registry specifies the primary endpoint time frame as 6 months after the last patient was evaluated. This is a study-level timing specification for the endpoint assessment rather than a statement that every participant was followed for exactly the same duration.
Why is randomization important for the PFS comparison?
Randomization provides the foundation for comparing outcomes between the treatment groups because treatment assignment is determined by the randomized design rather than by investigators or participants selecting treatment according to prognosis. The statistical analysis then compares the resulting time-to-event experience according to randomized assignment.
Why should a hazard ratio not be interpreted as a risk ratio?
A hazard ratio compares event rates at a given point in time under a time-to-event model. A risk ratio compares cumulative probabilities over a defined period. They are mathematically and conceptually different quantities, so a hazard ratio should not be relabeled as a relative risk or as a percentage of patients benefiting.
7. Interpreting a Future PFS Analysis
Although the registry does not report a numerical PFS result, the statistical structure of the endpoint allows several quantities to be distinguished clearly if results become available.
Kaplan-Meier curve
Shows how the estimated probability of remaining free from progression, relapse, or death changes over follow-up.
Median PFS
Would identify the time at which the estimated event-free survival probability reaches 50%, if that point is observed.
Hazard ratio
Would summarize the relative instantaneous event hazard between the randomized groups under a Cox model.
Confidence interval
Would quantify statistical uncertainty around an estimated treatment effect and indicate how precisely the effect has been estimated.
These measures should not be treated as interchangeable. A median PFS is an absolute time measure, whereas a hazard ratio is a relative model-based measure. A confidence interval describes uncertainty around an estimate; it does not describe the range of outcomes that individual patients will experience.
If a future analysis reported a hazard ratio below 1, the appropriate interpretation would be that the estimated instantaneous rate of the PFS event was lower in the treatment group represented in the numerator of the hazard ratio. The magnitude would describe a relative treatment effect under the fitted model, not the percentage of participants who avoided progression.
If a confidence interval were reported, its width would provide information about precision. A narrow interval would indicate greater statistical precision than a wide interval, all else equal. The interval would not describe the range of treatment effects experienced by individual patients.
A p-value would address the strength of evidence against a specified null hypothesis; it would not measure the size or clinical importance of the treatment effect. Effect size, uncertainty, and clinical context should therefore be considered separately.
8. Analysis Population and Randomization
The registry establishes that MIRACLE is randomized, with an enrollment of 200 participants and 2 arms. The available record does not provide arm-specific enrollment counts or additional analysis-population definitions.
| Design element | Registry information |
|---|---|
| Allocation | Randomized |
| Number of arms | 2 |
| Design model | Parallel |
| Total enrollment | 200 |
| Masking | None |
| Primary purpose | Treatment |
For a randomized efficacy analysis, an intention-to-treat approach is often the principal framework because it preserves the comparison created by randomization. However, the available registry record does not specify an analysis population definition, so a specific analysis population should not be attributed to the trial beyond the information recorded above.
9. Missing Data, Censoring, and Follow-Up
Progression-free survival necessarily raises questions about censoring and incomplete observation. A participant may reach the end of follow-up without experiencing progression, relapse, or death. That participant has contributed known event-free follow-up up to the censoring time, but the absence of an observed event does not establish indefinite event-free survival.
The registry's primary endpoint time frame is 6 months after the last patient was evaluated. The record does not specify a censoring algorithm, rules for lost-to-follow-up participants, missing assessment handling, imputation method, or sensitivity analyses.
For progression-based endpoints, the exact definition of what constitutes progression or relapse and the timing of assessments can materially affect the observed event times. The registry definition establishes the composite endpoint but does not provide additional assessment rules in the available record.
10. Proportional-Hazards Considerations
A Cox proportional-hazards analysis is commonly used for randomized PFS comparisons, but its interpretation depends on the proportional-hazards assumption. In simple terms, the model assumes that the relative hazard between treatment groups is reasonably stable over the relevant follow-up period.
An HR below 1 corresponds to a lower estimated event hazard in the numerator group. The HR is not an absolute probability and is not automatically equivalent to a percentage difference in PFS.
If hazards cross or the treatment effect changes substantially over time, a single hazard ratio can compress a more complicated pattern into one number. In such circumstances, Kaplan-Meier curves, fixed-time survival estimates, restricted mean survival time, or other time-varying summaries may provide additional insight.
The ClinicalTrials.gov record does not report a fitted Cox model or its diagnostics, so no conclusion about proportional hazards can be made for MIRACLE from the registry alone.
11. Multiplicity and Endpoint Structure
The registry identifies one registered primary endpoint: progression-free survival. It does not provide additional primary endpoints, a multiplicity-adjustment strategy, or an endpoint hierarchy in the available record.
| Endpoint role | Registry information | Statistical implication |
|---|---|---|
| Primary endpoint | Progression free survival | Primary time-to-event comparison |
| Additional primary endpoints | None identified in the available record | No additional primary-endpoint testing structure is reported |
| Multiplicity adjustment | Not reported | Cannot be characterized from the registry |
| Interim analysis | Not reported | No interim-testing framework is identified |
A single primary endpoint can simplify the statistical interpretation because there is no need to distinguish among several co-primary endpoints in the information available here. However, secondary or exploratory analyses can still introduce multiplicity if they are performed. The registry does not provide a statistical analysis plan describing such procedures.
12. Randomized Parallel Design: Statistical Implications
The parallel design means that participants are randomized to a treatment arm and followed within that assignment rather than routinely switching between treatment strategies. For a time-to-event endpoint, this creates a direct comparison of the event histories arising after randomization.
Parallel assignment
Each participant belongs to one randomized arm rather than serving as their own treatment-period control.
No masking
The registry identifies the trial as unmasked, so participants and investigators were not assigned to blinded treatment conditions.
Randomization
Randomized allocation provides the basis for a comparative efficacy analysis.
Time-to-event outcome
PFS uses the timing of progression, relapse, or death rather than a simple end-of-study proportion.
The absence of masking does not automatically invalidate a progression-free survival comparison. However, when an endpoint includes assessments that can be influenced by clinical judgment, knowledge of treatment assignment can potentially affect measurement or management. The registry's endpoint definition alone does not permit quantification of such an effect.
13. Trial Timeline
Trial start
The registry lists December 2014 as the study start date.
Primary completion
The registry lists December 2016 as the primary completion date.
Primary endpoint time frame
Progression-free survival is specified to be assessed using the time from randomization to disease progression, relapse, or death, with the registry time frame stated as 6 months after the last patient was evaluated.
The distinction between study completion and endpoint definition is important. A study completion date identifies a milestone in the conduct of the trial, whereas the PFS time frame describes when the primary endpoint is assessed relative to the last patient evaluation.
14. Statistical Interpretation of the Primary Endpoint
Progression-free survival combines three possible events into a single time-to-event endpoint: disease progression, relapse, or death. The endpoint therefore captures the time until the first qualifying event.
PFS is not identical to overall survival, tumor response, or quality of life. A PFS analysis specifically describes the time until the defined progression, relapse, or death event and should not be interpreted as a direct measure of every dimension of clinical benefit.
A median PFS, if reported, would answer an absolute time question. A hazard ratio, if reported, would answer a relative event-hazard question. Neither quantity alone fully describes the distribution of patient outcomes over time.
A p-value measures the compatibility of the observed data with a specified null hypothesis under the statistical testing framework. It does not tell readers how large the treatment effect is. The effect estimate and its confidence interval are required to describe magnitude and precision.
15. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The registered primary endpoint is a randomized time-to-event comparison of progression-free survival. Appropriate analysis would account for event timing and right censoring rather than reducing follow-up to a simple binary outcome.
Clinical interpretation
The endpoint concerns the duration from randomization until disease progression, relapse, or death. Its clinical meaning therefore depends on how differences in this time relate to the broader treatment objectives of metastatic breast cancer.
The two perspectives should remain distinct. Statistical analysis describes the evidence for a difference in the prespecified endpoint; clinical interpretation considers what that endpoint represents in the context of the disease and treatment strategy. Neither perspective should be substituted for the other.
16. Limitations
- No posted numerical results: The ClinicalTrials.gov record does not report a PFS estimate, hazard ratio, confidence interval, p-value, event count, or other primary efficacy result.
- Limited endpoint detail: The registry defines progression-free survival as time from randomization to disease progression, relapse, or death but does not provide additional assessment or censoring rules in the available record.
- Analysis methods not specified: The available record does not identify the exact statistical model, testing procedure, stratification factors, or analysis population used for PFS.
- Arm-level enrollment not reported: The total enrollment is 200, but the available record does not provide the number assigned to each of the two arms.
- Intervention assignment detail is limited: Everolimus, goserelin, and letrozole are identified as interventions, but the available record does not provide enough arm-specific detail to reconstruct the treatment regimens fully.
- No masking: The trial is identified as unmasked. Knowledge of treatment assignment can be relevant when endpoints involve clinical assessment.
- Unreported multiplicity and interim procedures: The available record does not specify a multiplicity strategy or interim-analysis framework.
- Unknown registry status: The ClinicalTrials.gov status is listed as UNKNOWN, so the registry record does not establish a current completed-trial status from the information available here.
These limitations primarily affect how far the statistical analysis can go. The trial design and primary endpoint can be described precisely, but a numerical treatment-effect interpretation requires an actual posted analysis containing the relevant event and model estimates.
17. Why This Trial Matters Statistically
MIRACLE provides a compact example of the statistical issues that arise whenever a randomized clinical trial uses progression-free survival as its primary endpoint. The trial combines randomization, parallel-group comparison, an unmasked design, and a composite time-to-event endpoint.
| Concept | How it appears in MIRACLE |
|---|---|
| Randomization | Participants were randomized to 2 arms. |
| Parallel design | The registry identifies a parallel-group design. |
| Phase 2 | The study is identified as a phase 2 trial. |
| Time-to-event analysis | The primary endpoint is progression-free survival. |
| Composite endpoint | PFS includes disease progression, relapse, or death. |
| Censoring | Time-to-event analysis must account for participants whose event-free observation ends before an event. |
| Kaplan-Meier estimation | A standard approach for describing PFS over time. |
| Hazard ratio | A standard model-based summary for comparing event hazards when a Cox model is appropriate. |
| Confidence intervals | Would quantify uncertainty around an estimated treatment effect. |
| Unmasked design | The registry identifies no masking. |
The trial is also a useful reminder that a statistical endpoint is more than a label. "Progression-free survival" encodes a specific time origin, a specific set of qualifying events, a follow-up process, censoring rules, and a statistical framework for comparing event histories. Each component affects the interpretation of the final estimate.
18. Sources
- ClinicalTrials.gov: MIRACLE, NCT02313051.
- PubMed: PubMed record associated with the trial.
Continue through the Clinical Biostats clinical trial library
Explore additional clinical-trial analyses and statistical resources covering study design, endpoints, survival analysis, and interpretation.
19. Record Summary
MIRACLE is a randomized phase 2 parallel-group trial in metastatic breast cancer with an enrollment of 200 participants and 2 arms. The registry identifies everolimus, goserelin, and letrozole as trial interventions and specifies progression-free survival as the primary endpoint. PFS is defined as the time from randomization to disease progression, relapse, or death, with the endpoint time frame listed as 6 months after the last patient was evaluated.
Statistically, the central feature of MIRACLE is therefore a randomized time-to-event comparison. A rigorous PFS analysis would normally describe the event-free distributions using Kaplan-Meier methods, compare randomized groups using an appropriate survival-testing framework, and potentially estimate a hazard ratio using a Cox model. Interpretation would require attention to censoring, proportional-hazards assumptions, confidence intervals, and the distinction between relative treatment effects and absolute event-free times.